Summit Therapeutics plc Notification Of Transactions Of Persons Discharging Managerial Responsibilities
January 15 2020 - 7:15AM
UK Regulatory
TIDMSUMM
Summit Therapeutics plc
("Summit Therapeutics" or the "Company")
Notification of Transactions of Persons Discharging Managerial
Responsibilities
Oxford, UK, and Cambridge, MA, US, 15 January 2020 - Summit Therapeutics
(AIM: SUMM, NASDAQ: SMMT), a leader in antibiotic innovation, announces
that it has received notification that on 14 January 2020, Mr Robert W.
Duggan, a Non-Executive Director of the Company, sold a total of
33,321,870 ordinary shares and transferred a total of 4,998,279 warrants
to various trusts as detailed below.
Number of Ordinary Sale Price per Number of Warrants
Name of Trust Shares Sold Ordinary Share* Transferred
------------------ ------------------ ------------------ ------------------
Daniel Douglas
Duggan Trust 1,753,780 22.1 pence 263,067
------------------ ------------------ ------------------ ------------------
Dante Eon Duggan
Trust 1,753,780 22.1 pence 263,067
------------------ ------------------ ------------------ ------------------
David Michael
Duggan Trust 1,753,780 22.1 pence 263,067
------------------ ------------------ ------------------ ------------------
Diamond Augustus
Duggan Trust 1,753,780 22.1 pence 263,067
------------------ ------------------ ------------------ ------------------
Diana Star Duggan
Trust 1,753,780 22.1 pence 263,067
------------------ ------------------ ------------------ ------------------
Dsara Ann Duggan
Trust 1,753,780 22.1 pence 263,067
------------------ ------------------ ------------------ ------------------
Dylan Duke Duggan
Trust 1,753,780 22.1 pence 263,067
------------------ ------------------ ------------------ ------------------
Mahkam Zanganeh
Revocable Trust 10,522,705 22.1 pence 1,578,405
------------------ ------------------ ------------------ ------------------
Shaun Zanganeh
Irrevocable
Trust 10,522,705 22.1 pence 1,578,405
------------------ ------------------ ------------------ ------------------
Total 33,321,870 4,998,279
------------------ ------------------ ------------------ ------------------
* The sale price per ordinary share has been converted from US Dollars
at an exchange rate of $1.2900 to GBP1.00.
Following the completion of these dealings, Mr Duggan has the following
interest in the Company's ordinary shares and warrants, respectively:
% of Issued
Shareholding Share Capital Warrants
----------------- ---------------- ------------ --------------- ----------
Non-Executive
Robert W. Duggan Director 211,123,385 62.85% 19,925,276
----------------- ---------------- ------------ --------------- ----------
This announcement contains inside information for the purposes of
Article 7 of EU Regulation 596/2014. The person responsible for
arranging for the release of this announcement on behalf of the Company
is Richard Pye, Vice President, Investor Relations and Corporate
Affairs.
About Summit Therapeutics
Summit Therapeutics is a leader in antibiotic innovation. Our new
mechanism antibiotics are designed to become the new standards of care
for the benefit of patients and create value for payors and healthcare
providers. We are currently developing new mechanism antibiotics to
treat infections caused by C. difficile, N. gonorrhoeae and
Enterobacteriaceae and are using our proprietary Discuva Platform to
expand our pipeline. For more information, visit www.summitplc.com and
follow us on Twitter @summitplc.
For more information, please contact:
Summit
Glyn Edwards / Richard Pye (UK office) Tel: 44 (0)1235 443 951
Michelle Avery (US office) +1 617 225 4455
Cairn Financial Advisers LLP (Nominated Adviser) Tel: +44 (0)20 7213 0880
Liam Murray / Tony Rawlinson / Ludovico
Lazzaretti
N+1 Singer (Joint Broker) Tel: +44 (0)20 7496 3000
Aubrey Powell / George Tzimas, Corporate Finance
Tom Salvesen, Corporate Broking
Bryan Garnier & Co Limited (Joint Broker) Tel: +44 (0)20 7332 2500
Phil Walker / Dominic Wilson
MSL Group (US) Tel: +1 781 684 6552
mailto:summit@mslgroup.com
Erin Anthoine summit@mslgroup.com
------------------------------
Consilium Strategic Communications (UK) Tel: +44 (0)20 3709 5700
Mary-Jane Elliott / Sue Stuart / mailto:summit@consilium-comms.
Sukaina Virji / Lindsey Neville com
summit@consilium-comms.com
------------------------------
The information set out below is provided in accordance with the
requirements of Article 19(3) of the Market Abuse Regulation (EU) No
596/2014.
1 Details of the persons discharging managerial responsibilities/person
closely associated
-----------------------------------------------------------------------------
a) Name (i) Robert W. Duggan
----------------------- ----------------------------------------------------
2 Reason for the notification
-----------------------------------------------------------------------------
a) Position / status (i) Non-Executive Director
----------------------- ----------------------------------------------------
b) Initial notification / Initial notification
Amendment
----------------------- ----------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------------
a) Name Summit Therapeutics plc
----------------------- ----------------------------------------------------
b) LEI 213800NRW8AOMYMTBD89
----------------------- ----------------------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
-----------------------------------------------------------------------------
a) Description of the Ordinary shares of 1 penny each
financial instrument,
type of instrument
Identification code GB00BN40HZ01
----------------------- ----------------------------------------------------
b) Nature of the Sale of ordinary shares of one penny nominal value
transactions
----------------------- ----------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
----------------------- --------------------------- -------------------
(i) 22.1p (exercise price) (i) 33,321,870
----------------------- --------------------------- -------------------
d) Aggregated information
- Aggregated volume 33,321,870 ordinary shares
- Price 22.1 pence
----------------------- ----------------------------------------------------
e) Date of the 14 January 2020
transactions
----------------------- ----------------------------------------------------
f) Place of the Outside a trading venue
transactions
----------------------- ----------------------------------------------------
1 Details of the persons discharging managerial responsibilities/person
closely associated
--------------------------------------------------------------------------------------
a) Name (ii) Robert W. Duggan
------------------------- -----------------------------------------------------------
2 Reason for the notification
--------------------------------------------------------------------------------------
a) Position / status (ii) Non-Executive Director
------------------------- -----------------------------------------------------------
b) Initial notification / Initial notification
Amendment
------------------------- -----------------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--------------------------------------------------------------------------------------
a) Name Summit Therapeutics plc
------------------------- -----------------------------------------------------------
b) LEI 213800NRW8AOMYMTBD89
------------------------- -----------------------------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
--------------------------------------------------------------------------------------
a) Description of the Ordinary shares of 1 penny each
financial instrument,
type of instrument
Identification code GB00BN40HZ01
------------------------- -----------------------------------------------------------
b) Nature of the Transfer of warrants to subscribe for ordinary shares
transactions of one penny nominal value
------------------------- -----------------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
------------------------- ---------------------- -------------------------------
(i) n/a (ii) 4,998,279
------------------------- ---------------------- -------------------------------
d) Aggregated information
- Aggregated volume 4,998,279 warrants to subscribe for ordinary shares
- Price n/a
------------------------- -----------------------------------------------------------
e) Date of the transactions 14 January 2020
------------------------- -----------------------------------------------------------
f) Place of the transactions Outside a trading venue
------------------------- -----------------------------------------------------------
-END-
(END) Dow Jones Newswires
January 15, 2020 07:15 ET (12:15 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Summit Therapeutics (LSE:SUMM)
Historical Stock Chart
From Oct 2024 to Nov 2024
Summit Therapeutics (LSE:SUMM)
Historical Stock Chart
From Nov 2023 to Nov 2024
